Clinical trials: Allogeneic Stem-Cell Transplant
Hematopoietic Stem Cell Transplantation
Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant
The purpose of this study is to determine whether vitamin D is effective in the prevention of graft-versus-host-disease after completion of allogeneic transplant.
- Trial name
- Alovita-1 (NCT02600988)
- Testing
- 1000IU/day of Vitamine D, 5000IU/day of Vitamine D
- Where
- 7 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hematologic Malignancies
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
This is an open-label, dose escalation Phase I study to evaluate the tolerability and efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients with hematologic malignancies after allogeneic…
- Trial name
- NCT02985554
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Graft Versus Host Disease in GI Tract
Fecal Microbiota Transplantation in aGvHD After ASCT
Acute graft-versus-host-disease (aGvHD) is a typical complication after allogeneic hematopoetic stem cell transplantation (ASCT).
- Trial name
- NCT03819803
- Testing
- Fecal microbiota transplantation
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Graz
Invasive Fungal Infection
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection
Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients receiving chemotherapy for leukemia, or submitted to stem cell transplantation.
- Trial name
- NCT01198236
- Testing
- Itraconazole
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
This phase II clinical trial is studying how well giving busulfan, fludarabine phosphate, and anti-thymocyte globulin followed by donor stem cell transplant and azacitidine works in treating patients with high-risk…
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia
- Trial name
- NCT01168219
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Azacitidine
- Where
- 17 sites in United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing…
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
- Trial name
- NCT01883219
- Testing
- TKIs
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03128034
- Testing
- Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma
- Trial name
- NCT02396134
- Testing
- CMVpp65-A*0201 peptide vaccine, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- City of Hope Medical Center
Childhood Cancer
Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation
Identifying the post-transplantation phase wherein neutrophils recover their ability to release NETs could shed new light on the mechanism responsible for the increased susceptibility to infection among these patients and aid in…
- Trial name
- NETs post HSCT (NCT01491230)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Invasive Aspergillosis
Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation
Via a prospective non-interventional study clinical outcome of patients with - and without - history of pre-existing invasive aspergillosis undergoing allo-HSCT will be assessed, in terms of non-relapse mortality overall…
- Trial name
- IPAT (NCT03014934)
- Where
- 8 sites in Germany, Italy and 4 more
- Volunteers
- 2,100 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Lupus Erythematosus, Stem Cell Transplant
Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord
Systemic lupus erythematosus (SLE) is a rare (prevalence: 40- 50/100 000 persons) heterogeneous auto-immune and auto-inflammatory disease (AD), affecting both sexes and all races, with a peak incidence / prevalence among black…
- Trial name
- MSC-SLE (NCT03562065)
- Testing
- mesenchymal stem cells
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
E Coli Infections, Allogenic Transplant Patients
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC…
- Trial name
- NCT06938867
- Testing
- SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
- Where
- 10 sites in United States
- Volunteers
- 66 people
- Sponsor
- SNIPR Biome Aps.
cGVHD
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
- Trial name
- THRIVE (NCT05919511)
- Testing
- Non-Interventional
- Where
- 37 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Incyte Corporation
Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease
Gut Decontamination In Pediatric Allogeneic Hematopoietic
This research study is for participants who are undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk for developing acute graft-versus-host disease (GVHD).
- Trial name
- NCT02641236
- Testing
- Vancomycin-polymyxin B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Immunological Pure Red Cell Aplasia
Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation
A quarter of allogeneic hematopoietic stem cell transplantation are performed in a situation of major ABO mismatch exposing patients to the risk of immunological pure red cell aplasia (PRCA) after transplant.
- Trial name
- ErythroSIM (NCT05559827)
- Testing
- Isatuximab
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia, Myelodysplastic Syndrome
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen.
- Trial name
- VIDAZA-DLI (NCT01541280)
- Testing
- Azacitidine, DLI
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Hepatitis B
Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant
Background: Stem cell transplants (SCTs) are important in treating many diseases. There are two main types of transplants. Autologous stem cells come from the person getting the cells.
- Trial name
- NCT03511794
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Waning Donor Chimerism, Waning Immune Function
CD34+ Stem Cell Infusion to Augment Graft Function
The purpose of this study is to determine if infusing additional special donor cells will help to improve graft or immune function in previously transplanted children with immune deficiencies and bone marrow failures.
- Conditions
- Waning Donor Chimerism, Waning Immune Function, Primary Immunodeficiency Disease(s), Bone Marrow Failure
- Trial name
- NCT01856582
- Testing
- CD34+
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
GATA2, Immunodeficiency
Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency
Background: People with GATA-binding factor 2 (GATA2) deficiency have a mutation on the GATA2 gene. This gene affects immune function.
- Trial name
- NCT05907746
- Testing
- Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy
Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation
This phase I/II study the side effects and efficacy of natural killer cells after donor stem cell transplant and how they treat patients with myeloid malignancies or lymphoproliferative disorders.
- Trial name
- NCT05250362
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sichuan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.